 By David Bautz, PhD NYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Business Update Enrollment Complete for Phase 2 Trial of AGO13 in Oral Mucositis Oragenics, Inc. NYSE:OGEN is currently conducting a Phase 2 clinical trial of its lead development compound AG013 in the prevention of severe oral mucositis OM. AG013 is an oral mouth rinse composed of a recombinant Lactococcus lactis strain that 